Rafael Baez Bonilla, MD
Nephrology · Fort Lauderdale, FLNPI 1427243310
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $139,852 of the $174,619 with a category attached, or 80.1%. Amgen accounts for 93.2% of it on its own, with 29 other manufacturers making up the rest. Reporting peaked in 2022 at $55,208 and has fallen 58.3% since, to $23,046 in 2025. Among nephrology clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 443 payments — averaging $394.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$163K
- Sobi, Inc$3K
- Otsuka America Pharmaceutical, Inc.$3K
- AstraZeneca$800
- Travere Therapeutics, Inc.$738
- Mallinckrodt Hospital Products Inc.$699
- plus $4K from 24 others
What the payments were for
- Consulting fees$5,3203%
- Speaking & faculty fees$139,85280%
- Travel & lodging$17,28910%
- Food & beverage$11,9327%
- Education$2260%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 192 | $162,818 |
| Sobi, Inc | 2 | $3,125 |
| Otsuka America Pharmaceutical, Inc. | 19 | $2,637 |
| AstraZeneca(2 entities) | 29 | $800 |
| Travere Therapeutics, Inc. | 27 | $738 |
| Mallinckrodt Hospital Products Inc. | 27 | $699 |
| GSK | 12 | $485 |
| Bayer | 12 | $346 |
| ANI Pharmaceuticals, Inc. | 12 | $341 |
| Vifor Pharma, Inc. | 17 | $341 |
| Calliditas Therapeutics US Inc. | 8 | $305 |
| Boehringer Ingelheim | 11 | $230 |
| Ardelyx, Inc. | 11 | $221 |
| Kyowa Kirin, Inc. | 8 | $204 |
| Novartis | 9 | $171 |
| Novo Nordisk | 7 | $169 |
| OPKO Pharmaceuticals, LLC | 8 | $168 |
| Aurinia Pharma U.S., Inc. | 7 | $164 |
| Akebia Therapeutics Inc | 6 | $141 |
| Vantive US Healthcare LLC | 1 | $118 |
| Lilly USA, LLC | 4 | $94 |
| Merck | 3 | $56 |
| Alnylam Pharmaceuticals Inc. | 2 | $53 |
| Arbor Pharmaceuticals, Inc. | 2 | $35 |
| Mallinckrodt Enterprises LLC | 2 | $33 |
| Baxter Healthcare | 1 | $33 |
| Scpharmaceuticals Inc. | 1 | $31 |
| Ultragenyx Pharmaceutical Inc. | 1 | $22 |
| Phathom Pharmaceuticals, Inc. | 1 | $22 |
| Fresenius USA Marketing, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$174,619 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 41 | $47,026 |
| KerendiaFinerenone | 12 | $10,110 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $10,001 |
| ProsolParenteral Amino Acid 20% No.1 | 31 | $6,326 |
| Calcium Acetate | 11 | $1,278 |
| Nifedipine ErNifedipine | 21 | $806 |
| Febuxostat | 12 | $589 |
| Bumetanide | 11 | $517 |
| Torsemide | 21 | $376 |
| Allopurinol | 41 | $295 |
| Losartan Potassium | 21 | $187 |
| Lisinopril | 45 | $171 |
| Spironolactone | 11 | $119 |
| Hydralazine Hcl | 20 | $118 |
| Furosemide | 18 | $92 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $800 | $57,02754 claims |
| BayerKerendia | $346 | $10,11012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 756 nephrology providers in Florida.
Other nephrology in Fort Lauderdale
- Carlos BejarFort Lauderdale$530K
- Wayne KotzkerFort Lauderdale$472K
- Reinaldo RosarioFort Lauderdale$75K
- Parham EftekhariFort Lauderdale$22K
- Arvind MadanOrlando$943K
- John CopleyWeston$934K
- Jorge LarranagaKissimmee$825K
- Jason RothschildTemple Terrace$413K
- Daniel PatelDaytona Beach$227K
- Gabriel ContrerasMiami$133K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.